In the Editorial entitled “Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors” that appeared in the August 2022 issue of AJKD (Palmer and Clegg, volume 80, issue 2, pages 159-160), there was an error in the financial disclosure statement. The corrected statement is “Financial Disclosure: Dr Palmer reports receipt of consultancy and speaker fees from Relypsa and AstraZeneca. Dr Clegg is the spouse of Dr Palmer.”